Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

GermanyBack to Germany

Clinical trials in Ulm – page 14

578 clinical trials in Ulm, Germany across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Ulm at a glance
578
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

578 trials in Ulm

Open in trial search

Dry age-related macular degeneration+1

Recruiting

Study of Pozelimab and Cemdisiran for Adults with Geographic Atrophy from Age-Related Macular Degeneration

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cemdisiran
  • Sponsor:Regeneron Pharmaceuticals Inc.

Crohn's disease

Recruiting

Study on the Effectiveness and Safety of Obefazimod for Patients with Moderate to Severe Crohn's Disease After Inadequate Response to Other Treatments

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Obefazimod
  • Sponsor:Abivax

Breast cancer+1

Recruiting

A Study of Trastuzumab Deruxtecan Treatment for Patients with Early-Stage HER2-Positive or HER2-Low Breast Cancer Who Show Signs of Molecular Relapse

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Trastuzumab Deruxtecan
  • Sponsor:Universitaetsklinikum Ulm AöR

Chronic graft versus host disease

Recruiting

Study on Axatilimab and Corticosteroids for Initial Treatment of Chronic Graft-Versus-Host Disease in Patients

Registered drug
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Incyte Corp.

Malignant peritoneal neoplasm+2

Recruiting

Comparison of niraparib alone versus niraparib with bevacizumab in patients with newly diagnosed advanced ovarian cancer after chemotherapy with carboplatin and paclitaxel

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:AGO Research GmbH

Pancreatic carcinoma metastatic

Recruiting

Study of Ginisortamab with Nab-Paclitaxel and Gemcitabine or MEK Inhibitor for Patients with Metastatic Pancreatic Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cobimetinib
  • Sponsor:Cancer Research UK

Colorectal cancer

Recruiting

Study Comparing Amivantamab and Chemotherapy Versus Cetuximab and Chemotherapy for Patients with Advanced Colorectal Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Amivantamab
  • Sponsor:Janssen Cilag International

Systemic candida

Recruiting

Study on the Effectiveness and Safety of Fosmanogepix Compared to Caspofungin and Fluconazole for Adults with Candidemia or Invasive Candidiasis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Caspofungin
  • Sponsor:Basilea Pharmaceutica International AG Allschwil

Nervous system disorder

Recruiting

Study on the Physical Impact of Multiple Sclerosis and Continued Access to Ocrelizumab for Patients Previously in a Related Study

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ocrelizumab
  • Sponsor:F. Hoffmann-La Roche AG

T-cell type acute leukaemia

Recruiting

Study on the Safety and Effectiveness of Isatuximab and Drug Combination for Adults with Relapsed or Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Goethe University Frankfurt

Acute leukaemia

Recruiting

Study on the Safety and Tolerability of SNDX-5613 for Patients with Relapsed or Refractory Acute Leukemias

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Revumenib
  • Sponsor:Syndax Pharmaceuticals Inc.

Plasma cell myeloma

Recruiting

Study Comparing Elranatamab, Daratumumab, and Lenalidomide with Daratumumab, Lenalidomide, and Dexamethasone for Patients with Newly Diagnosed Multiple Myeloma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib
  • Sponsor:Pfizer Inc.

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Ulm

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focusing on colorectal cancer, acute myeloid leukemia, and various types of lymphomas. Studies are evaluating novel combination therapies and targeted treatments for patients with specific genetic mutations.

  • Metastatic Colorectal Cancer Treatment
  • B-Cell Lymphoma Therapies
  • Advanced Breast Cancer Studies

Multiple trials investigating innovative treatment approaches for blood cancers and solid tumors.

02 Neurological Disorders

Clinical research targeting multiple sclerosis, Alzheimer's disease, and amyotrophic lateral sclerosis. Studies are exploring new therapeutic agents and diagnostic tools.

  • Early-Stage Alzheimer's Treatment
  • Progressive MS Therapies
  • ALS Gene-Targeted Treatments

Innovative approaches in neurodegenerative disease management and treatment.

03 Autoimmune Conditions

Comprehensive studies on inflammatory bowel diseases, rheumatoid arthritis, and Sjögren's disease. Research focuses on novel biological therapies and long-term treatment options.

  • Crohn's Disease Treatments
  • Ulcerative Colitis Management
  • Autoimmune Disorder Therapies

Advanced therapeutic approaches for chronic inflammatory conditions.

Back to GermanyAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.